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The Government is Wrong: The Case for Human Gene Patents and the 
Genomics Revolution
by Jonathan Stroud 
Editor’s note: The following blog post was posted on www.ipbrief.net on 
November 2nd, 2010. 
The news media kicked up quite a fuss this spring 
when a U.S. district court invalidated the patents on 
two isolated genes that are strong indicators of a risk 
of breast cancer.  Association for Molecular Patenting 
v. United States Patent and Trademark Association, 
1:09-cv-04515-RWS (S.D.N.Y. Mar. 29, 2010); see 
Blog Post of Kevin E. Noonan, Myriad Appeals AMP 
v. USPTO Decision  (June 16, 2010) (collecting news 
articles and blog posts).  The genes in question, BRCA1 
and BRCA2, were researched, located, isolated, and 
patented by Myriad Genetics, one of the older genetics 
start-up companies (founded in 1991).  They are among 
over 2,000 existing gene patents, which grant market 
exclusivity to inventors who have put in the work to 
identify and isolate specific human genes.  Friday, the 
U.S. government unexpectedly reversed its previously 
held position supporting such patents, and issued a 
friend-of-the-court brief in the appeal of that case 
condemning the patenting of isolated human genes.  
Association for Molecular Patenting v. United States 
Patent and Trademark Association, No. 2010-1406, 
Amicus Curiae Brief for the United States in Support 
of No One (Fed. Cir.) (filed Oct. 29, 2010).
The government is wrong.  Because it will fuel 
scientific progress, give a reasonable financial incentive 
to companies interested in genomics, and lead to 
further research in this rapidly expanding field, not to 
mention the fact that it is consistent with prevailing 
Federal Circuit precedent, the court should overturn 
this dangerous ruling.  The government should not 
support the ruling, which in effect would invalidate 
over 2,000 genomic patents.  Instead, Congress should 
selectively enact compulsory licenses on genetics 
patents when the test and gene in question are so 
significant that leaving the testing in the hands of one 
company puts potentially life-saving testing out of the 
reach of the average consumer.  A sliding scale is more 
appropriate than the current all-or-nothing approach.  
First, background is important.  Myriad is a 
pioneer in a financially uncertain but potentially 
revolutionary field.  In his recent book Dr. Francis 
Collins, the lead scientist in charge of the initial 
mapping of the human genome and the current head 
of the National Institute of Health, predicts that the 
most significant change in health care will come from 
advancements in genetic testing.  Francis S. Collins, 
The Language of Life (2010).  Three companies already 
offer personalized human genome mapping, and Dr. 
Collins predicts this will soon become a mandatory 
test required at birth and included in all individuals’ 
health records, as scientists isolate and characterize 
more and more genes and their hereditary effects.  Id. 
at 44.  (“Newborn screening [which already occurs for 
very specific and treatable genetic conditions, such as 
cystic fibrosis] seems almost certain to evolve into an 
even broader and more comprehensive survey. . . . A 
softer version of GATTACA may be coming soon.”)   
Genes BRCA1 and 2 are well known in the 
genomics field as some of the first genes whose 
common genetic mutations show a significant increase 
in the risk of a specific, treatable, and even sometimes 
preventable condition, breast cancer.  Id. at 27 
(“women who carry a BRCA1 mutation have about 
an 80 percent lifetime risk of developing breast cancer 
and a 50 percent risk of developing ovarian cancer.”).  
Myriad was the first to identify a method of testing 
for the genes and has moved to protect its interest as 
the sole holder of a suite of patents for those isolation 
and testing methods.  Myriad, attempting to remain 
profitable while conducting further research and 
recouping the investment it has already put in through 
its initial research, is charging roughly $3,000 for the 
test.  AMP v. USPTO 1:09-cv-04515-RWS. at 52-78. 
The ACLU, breast cancer interest groups, and now 
the U.S. government oppose these patents as profiting 
from what is essentially our own human body, which 
they argue violates the statutory grant to the USPTO 
under 35 U.S.C. § 101, violates our individual First 
Amendment rights, and prevents lifesaving testing 
from being widely used.  Their opposition is too 
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extreme, misunderstands the important place of 
industry in genetic research, and makes it harder for 
technology and research in genomics to grow at the 
current rapid pace.  Furthermore, it is consistent with 
all of the known precedent concerning gene isolation 
patents, as well as with the over 2,000 patents the 
USPTO has granted consistent with their policies. 
To be sure, no one wants important and potentially 
life-saving tests for breast cancer to be out of reach of 
the American public.  That is why a congressionally 
mandated compulsory license is more appropriate for 
genetic tests of strong indicators of treatable serious 
conditions, particularly in the case of public hospitals 
and research institutions.  Such a license would allow 
other companies and researchers to use the tests for a 
set licensing fee, and in certain limited cases, for free, 
which would reward and compensate Myriad for their 
research while striking the balance with public access 
to the tests.  
However, simply invalidating the patents would 
give Myriad and other genetic start-up companies 
absolutely no incentive to research in this volatile 
and uncertain field, and will actually stifle genomic 
innovation in the end at a key time in the industry’s 
adolescence.  In a perfect world, well-funded 
government researchers in highly regarded public 
universities and research centers would exclusively 
carry out this important work, they would excel in 
the endeavor, and that would be sufficient.  But absent 
some windfall grant of funding to the NIH or some 
newly instituted and very well-funded prize program, 
Congress needs to act to limit the reach of such 
intellectual property while ignoring a more sweeping 
and dangerous open grant, which offers no incentives 
whatsoever for companies to invest in key lifesaving 
research.  To invalidate these patents would be far more 
dangerous to our health in the long run, and would put 
our industry and nation at a disadvantage worldwide 
in one of the only scientific fields in which we are still a 
leader, the genomics revolution. 
